| Description | GSK2292767 is a potent and selective PI3Kδ inhibitor.This compound is unstable in powder form and other related salt forms are recommended. |
| In vitro | BI-847325对BRAF突变和对vemurafenib有抗药性的黑色素瘤细胞显示出增长抑制效果，IC50值介于0.3 nM到2 μM之间，并且能防止六种BRAF突变的黑色素瘤细胞系的集群形成。BI-847325还通过降低Mcl-1表达来诱导细胞凋亡。[1] |
| In vivo | GSK2292767在选择性上显著偏向PI3Kδ，相较于其他密切相关的同型体而言。在与疾病相关的布朗挪威鼠急性OVA模型中，针对Th2驱动的肺部炎症显示出活性[1]。 |
| molecular weight | 512.58 |
| Molecular formula | C24H28N6O5S |
| CAS | 1254036-66-2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 93 mg/mL (181.4 mM) Ethanol: <1 mg/mL H2O: <1 mg/mL |
| References | 1. Down K, et al. J Med Chem. 2015, 58(18):7381-7399. |